Idebenone
Pre-clinicalCompleted 0 watching 0 views this week💤 Quiet
15
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Leber's Hereditary Optic Neuropathy (LHON)
Conditions
Leber's Hereditary Optic Neuropathy (LHON)
Trial Timeline
Sep 1, 2016 → Apr 16, 2021
NCT ID
NCT02771379About Idebenone
Idebenone is a pre-clinical stage product being developed by Santhera Pharmaceuticals for Leber's Hereditary Optic Neuropathy (LHON). The current trial status is completed. This product is registered under clinical trial identifier NCT02771379. Target conditions include Leber's Hereditary Optic Neuropathy (LHON).
Hype Score Breakdown
Clinical
5
Activity
2
Company
2
Novelty
2
Community
1
Clinical Trials (6)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03433807 | Pre-clinical | Completed |
| NCT02771379 | Pre-clinical | Completed |
| NCT02774005 | Approved | Completed |
| NCT00758225 | Phase 2 | Completed |
| NCT00697073 | Phase 3 | Completed |
| NCT00993967 | Phase 3 | Completed |
Competing Products
4 competing products in Leber's Hereditary Optic Neuropathy (LHON)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Idebenone + Placebo | Santhera Pharmaceuticals | Phase 2 | 44 |
| Idebenone | Santhera Pharmaceuticals | Approved | 77 |
| Idebenone 150 MG Oral Tablet | Santhera Pharmaceuticals | Pre-clinical | 15 |
| Idebenone + Placebo | Santhera Pharmaceuticals | Phase 3 | 69 |